According to the findings of a study issued in 'Cureus', sequential therapy was more effective than triple therapy in people infected with H. pylori. This randomized clinical trial was carried out to compare effectiveness of sequential therapy and triple therapy to eliminate H. pylori. Overall, 160 participants (mean age = 40.02) were recruited and segregated into group A (n = 54) and group B (n = 76). The ratio of men/women was 1.8:1.

For 10 days, a twice-daily dose of 500 mg clarithromycin, 20 mg rabeprazole, and 1000 mg amoxicillin was administered to group A. Initially, group B received 20 mg rabeprazole and 1000 mg amoxicillin twice daily for the first 5 days (i.e., induction phase). This was subsequently followed by triple therapy encompassing 500 mg tinidazole/metronidazole, 500 mg clarithromycin, and 20 mg rabeprazole 2 times a day for the next 5 days.

A negative stool antigen test conducted 4 weeks post-therapy completion was considered to be an efficacious H. pylori elimination. For the collection of data, a proforma was utilized that encompassed eradication effectiveness, group (group A or group B), family income, province or city of residence, gender, and age. Evaluation of data was done. Compared to Group A, a higher percentage of patients in Group B witnessed successful H. pylori elimination, as shown in Table 1:

To determine H. pylori eradication, the stool antigen test was reported to be efficient and noninvasive. Hence, for the management of H. pylori infection, sequential therapy exhibited superiority over triple therapy across all ages and genders.